A randomized phase II trial of pertuzumab in combination with trastuzumab with or without chemotherapy, both followed by T-DM1 in case of progression, in patients with HER2-positive metastatic breast cancer

Projekt

A randomized phase II trial of pertuzumab in combination with trastuzumab with or without chemotherapy, both followed by T-DM1 in case of progression, in patients with HER2-positive metastatic breast cancer

Automatisch geschlossen · 2013 bis 2019

Weder Patrik, Thürlimann Beat, Ruhstaller Thomas, Maier Reinhard, Riniker Salome, Öhlschlegel Christian, Hasler-Strub Ursula

Art

Klinische Forschung

Reichweite

Multizentrisch, KSSG als Hauptzentrum

Bereiche

Medizinische Onkologie und Hämatologie, Brustzentrum St.Gallen, Medizinisches Forschungszentrum, Clinical Trials Unit, Pathologie

Status

Automatisch geschlossen

Start

2013

Ende

2019

Finanzierungsart

Andere

Studiendesign

Multicenter, randomized, open label, phase II trial.

Kurzbeschreibung/Zielsetzung

The primary objective of this trial is to evaluate the efficacy in terms of overall survival (OS) at 24 months of a chemotherapy-free dual HER2-inbibition with trastuzumab and pertuzumab (first-line) followed by T-DM1 (second-line) and of a chemotherapy-containing dual HER2-inhibition with trastuzumab and pertuzumab (first-line) followed by T-DM1 (second-line) in patients with HER2-positive metastatic breast cancer.